Species | Target name | Source | Bibliographic reference |
---|---|---|---|
Rattus norvegicus | Angiotensin II type 2 (AT-2) receptor | Starlite/ChEMBL | No references |
Oryctolagus cuniculus | Angiotensin II type 1a (AT-1a) receptor | Starlite/ChEMBL | No references |
Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
IC50 (binding) | = 2.2 nM | Tested for its ability to displace the specific binding ligand [125I]-Sar 1,lle8-AlI from rabbit aortic membrane (AT1 receptor) | ChEMBL. | No reference |
IC50 (binding) | = 2.2 nM | Tested for its ability to displace the specific binding ligand [125I]-Sar 1,lle8-AlI from rabbit aortic membrane (AT1 receptor) | ChEMBL. | No reference |
IC50 (binding) | = 760 nM | Tested for its ability to displace the specific binding ligand [125I]-Sar 1,lle8-AlI from rat midbrain membrane (AT2 receptor) | ChEMBL. | No reference |
IC50 (binding) | = 760 nM | Tested for its ability to displace the specific binding ligand [125I]-Sar 1,lle8-AlI from rat midbrain membrane (AT2 receptor) | ChEMBL. | No reference |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.